Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by IslandCowboyon Apr 01, 2021 11:09am
169 Views
Post# 32922673

Agree with Bully!

Agree with Bully!I see this as an amazing, profitable direction for this company to take. Why have just the shell and not the whole enchilada? Aristotle"s ground breaking ability for early diagnosis of 10 different cancers has not changed. The whole scope of care for the patients receiving a life altering diagnosis has been stepped up and expanded however likened to one stop shopping. They are taken " into the fold" and care is initiated immediately. It only makes sense and exudes compassion that you as a patient facing hurdles are already entered into a line of care. I see future expansion with psychologists and social workers involved in these clinics to help these patients deal emotionally with their diagnosis and picking up the pieces and formulating their plan of care. I say brilliant design that has a global outlook despite the way the information was executed to the shareholders. I for one am holding my shares. 
<< Previous
Bullboard Posts
Next >>